Payment overview · 2025
General Payments
$1,906.38
87 reported records · 18 companies
Healthcare provider profile · identity verified
Muhammad H Iqbal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND, KY · NPI 1356547491
Verified facts
What the public records show
CMS Open Payments records show Muhammad H Iqbal, MD received $1,906.38 in general payments during 2025 across 87 reported records.
GlaxoSmithKline, LLC. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Glassia, Trelegy Ellipta, Wakix, Xolair.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 487 claims for Trelegy Ellipta by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wakix by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xolair by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $426.34 | 22.4% | 25 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.17 | 10.2% | 10 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $186.64 | 9.8% | 6 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $160.32 | 8.4% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $119.58 | 6.3% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $110.00 | 5.8% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $104.78 | 5.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $99.94 | 5.2% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $95.00 | 5.0% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $82.47 | 4.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.17 | 3.7% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $66.21 | 3.5% | 5 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $52.43 | 2.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.86 | 2.7% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $30.74 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.51 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.33 | 1.0% | 1 | 2025 |
| ZOLL Circulation Inc | Unresolved — no canonical attribution shown | $16.89 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,806.39 | 86 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $265.03 | 17 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $161.31 | 8 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $160.32 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $160.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $160.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $160.32 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $159.47 | 8 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $121.24 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $119.58 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $110.00 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $104.78 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $95.00 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $86.65 | 5 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $82.47 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $72.65 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.95 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $66.21 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.55 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $50.86 | 3 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Catheter Normalized: catheter |
Device | ZOLL Circulation Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Downstream Cartridge Normalized: downstream cartridge |
Device | ZOLL Circulation Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| TherOx DS2 Console Normalized: therox ds2 console |
Device | ZOLL Circulation Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GLASSIA glassia |
2025 | Glassia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 487 | exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XOLAIR xolair |
2025 | Xolair | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
487 | 153 |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 542 | 222 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 487 | 153 |
| Azelastine Hcl | Azelastine Hcl | 397 | 204 |
| Montelukast Sodium | Montelukast Sodium | 310 | 106 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 305 | 101 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 253 | 96 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 96 |
| Spiriva Respimat | Tiotropium Bromide | 200 | 69 |
| Breo Ellipta | Fluticasone/Vilanterol | 139 | 46 |
| Roflumilast | Roflumilast | 132 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 127 | 49 |
| Temazepam | Temazepam | 114 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 113 | 38 |
| Flunisolide | Flunisolide | 86 | 45 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 70 | 35 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 25 |
| Arnuity Ellipta | Fluticasone Furoate | 51 | 16 |
| Prednisone | Prednisone | 51 | 40 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 22 |
| Atrovent Hfa | Ipratropium Bromide | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Dulera | Mometasone/Formoterol | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Armodafinil | Armodafinil | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Xolair | Omalizumab | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
| Wakix | Pitolisant Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,906.38 · 87 records | GlaxoSmithKline, LLC. | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CHARTIS CATHETER, Catheter, DUPIXENT, Downstream Cartridge, FASENRA, GLASSIA, JASCAYD, NUCALA, OFEV, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, Prolastin-C Liquid, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, TherOx DS2 Console, Tyvaso, Vest Therapy Und, WAKIX, XOLAIR, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Glassia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error